Group 4 Created with Sketch.
Episode 51 of 125

Expert Answers to Questions on PARP Inhibition for Prostate Cancer

Play Audio
Add to Playlist
Share Report
Snippets are a new way to share audio!
You can clip a small part of any file to share, add to playlist, and transcribe automatically. Just click the to create your snippet!
Top Snippets - Expert Answers to Questions on PARP Inhibition for Prostate Cancer
Found on these Playlists
Add to Playlist
Full Description
Back to Top
In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:Germline and somatic mutation testingManaging adverse events with PARP inhibitorsResistance to PARP inhibitorsImplications of monoallelic vs biallelic BRCA mutationsATM mutations and PARP inhibitor sensitivityPresenters:Charles J. Ryan, MDProfessor of MedicineB.J. Kennedy Chair in Clinical Medical OncologyDirector, Division of Hematology, Oncology and TransplantationDepartment of MedicineUniversity of MinnesotaOncologistDivision of Hematology, Oncology and TransplantationUniversity of Minnesota Health Clinics and Surgery CenterMinneapolis, MinnesotaNeal D. Shore, MD, FACSDirectorCarolina Urologic Research CenterAtlantic Urology ClinicsMyrtle Beach, South CarolinaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast: